APA (7th ed.) Citation

MS, R., Jr, M. M., CK, P., ST, P., RL, G., R, G., . . . SJ, S. (2020). A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. Vaccine, 38(45), 7040. https://doi.org/10.1016/j.vaccine.2020.09.025

Chicago Style (17th ed.) Citation

MS, Riddle, et al. "A First in Human Clinical Trial Assessing the Safety and Immunogenicity of Transcutaneously Delivered Enterotoxigenic Escherichia Coli Fimbrial Tip Adhesin with Heat-labile Enterotoxin with Mutation R192G." Vaccine 38, no. 45 (2020): 7040. https://doi.org/10.1016/j.vaccine.2020.09.025.

MLA (9th ed.) Citation

MS, Riddle, et al. "A First in Human Clinical Trial Assessing the Safety and Immunogenicity of Transcutaneously Delivered Enterotoxigenic Escherichia Coli Fimbrial Tip Adhesin with Heat-labile Enterotoxin with Mutation R192G." Vaccine, vol. 38, no. 45, 2020, p. 7040, https://doi.org/10.1016/j.vaccine.2020.09.025.